Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allergy & Immunology
Pharmaceutical company launches epinephrine auto-injector for anaphylaxis
September 14th, 2005
Verus Pharmaceuticals, Inc., a pediatric-oriented company, announced the U.S. launch of Twinject, an epinephrine auto-injector indicated for the emergency treatment of severe allergic reactions (anaphylaxis). Twinject is approved by the U.S. Food and Drug Administration (FDA) and contains two doses of epinephrine in a single device. Twinject is available in 0.3 mg, 0.15 mg, 0.3 mg two-pack, and 0.15 mg two-pack configuations Each two-pack configuration contains two devices for self-administration and a demonstrator for patient training purposes. Anaphylaxis is a severe, life-threatening systemic allergic reaction triggered by exposure to one or more...
Source: Vaccine Weekly (2005-09-14)
|
